- Forbes•6 days ago
Everytime Donald Trump tweets about drug prices, biotech stocks take it on the chin. Bruce Pile believes these episodes are giving informed investors good entry points for some of the best names in biotech.
- Reuters•2 years ago
Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease. The treatments are awaiting U.S. approval decisions after receiving breakthrough therapy designations from the Food and Drug Administration. "This is sort of a momentous year for us," Alexion Chief Executive David Hallal said in an interview.
- GuruFocus.com•2 years ago
Chicago-based Columbia Wanger (Trades, Portfolio) serves mostly investment companies, managing mutual funds for its clients.
GEVA : Summary for Synageva BioPharma Corp. - Yahoo Finance
Synageva BioPharma Corp. (GEVA)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
At close: 3:59PM EDT
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|